EC Number   |
Inhibitors |
Structure  |
|---|
    3.1.4.17 | more |
inhibition by monoclonal antibodies |
 |
| 3.1.4.17 | more |
- |
|
| 3.1.4.17 | more |
not inhibitory: EDTA up to 2.5 mM |
|
| 3.1.4.17 | more |
IC50 for vardenafil, sildenafil and tadalafil is above 10000 nM, PDE2 |
|
| 3.1.4.17 | more |
treatment with oxidant t-butylhydroperoxide results in release of significant amounts of interleukin-8, which is prevented by inhibition of enzyme isoforms PDE1 and PDE4 |
|
| 3.1.4.17 | more |
the oxidant t-butylhydroperoxide signifcantly increases the cytosolic calcium concentration, which is prevented by inhibition of enzyme isoform PDE1. Inhibition of both isoforms PDE1 and PDE4 completely prevent the t-butylhydroperoxide stimulated TNF-alpha release |
|
| 3.1.4.17 | more |
NAD+ is not an inhibitor of PDE3A |
|
| 3.1.4.17 | more |
not inhibited by rolipram and sildenafil |
|
| 3.1.4.17 | more |
PdeA and PdeB are not stimulated by 3-isobuthyl-1-methylxanthine, theophylline, beta-glycerophosphate, Ca2+, Mg2+, Fe2+, and Fe3+ |
|
| 3.1.4.17 | more |
the broad-spectrum phosphodiesterase inhibitor 3-isobutyl-1-methylxanthine, IBMX, has no effect on the activity of PdeE at 1 mM. No inhibition by theophylline at 1 mM, beta-glycerophosphate at 0.1 mM, and by orthovanadate |
|
